Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Patent Reform Legislation Proposes Sweeping Changes to U.S. Patent Laws

Milestone - Thank You!  It appears I am correct in my understanding, with the exception/variation in this case being the express language in the licensing agreement.  However, we too are (perhaps) limited by the first sale doctrine, and if that doctrine is upset by a change made by the SC, it is to our potential advantage.  And it appears that no matter how this case shakes out with the SC, we'll be no worse off than we are today.  Thus, my question stands, why all the negative excitement?  I think you posted something similar to this.  We're both posting in response to people suggesting something bad couold come of it - but I can't see how.

And I'll again say that, in light of the first sale doctrine, it's good that ARM is out of the picture, and that we should work our way up the supply chain, because if we start at the top, it ends there for that supplier and all their customers.

 Thanks again.  Please advise if I err in my reasoning.

SGE 

Share
New Message
Please login to post a reply